Clinical Trials Logo

Filter by:
NCT ID: NCT00049998 Completed - Clinical trials for Non-Small-Cell Lung Cancer

Oral Topotecan Versus Intravenous Docetaxel In Pretreated, Advanced Non-Small Cell Lung Cancer

Start date: October 2001
Phase: Phase 3
Study type: Interventional

The purpose of this study is to collect information on how effective and how well tolerated an oral investigational drug is compared to a standard intravenous drug in patients with pretreated, advanced non-small lung cancer (NSCLC).

NCT ID: NCT00045760 Completed - Sepsis Clinical Trials

The Study of Drotrecogin Alfa (Activated) in a Subpopulation of Adult Patients With Severe Sepsis

Start date: September 2002
Phase: Phase 4
Study type: Interventional

Severe sepsis is defined as a systemic inflammatory response syndrome that results from infection and is associated with acute organ dysfunction. It usually results from bacterial infections, but it may occur in response to other pathogens, such as fungi, viruses, and parasites.

NCT ID: NCT00044824 Completed - Asthma Clinical Trials

Efficacy and Safety of Fexofenadine in Mild to Moderate Persistent Asthma

Start date: February 2002
Phase: Phase 3
Study type: Interventional

The purpose of this study is to investigate the efficacy and safety of fexofenadine 120mg BID compared to placebo in the treatment of subjects with mild to moderate persistent asthma

NCT ID: NCT00044811 Completed - Asthma Clinical Trials

Efficacy and Safety of Fexofenadine in Mild to Moderate Persistent Asthma

Start date: March 2002
Phase: Phase 3
Study type: Interventional

The purpose of this study is to investigate the efficacy and safety of fexofenadine 120mg BID compared to placebo in the treatment of subjects with mild to moderate persistent asthma

NCT ID: NCT00044291 Completed - Breast Neoplasms Clinical Trials

Phase III Study of Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer

Start date: June 2002
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine whether the first line combination hormonal therapy of an experimental drug, atamestane, plus an FDA-approved drug, toremifene (Fareston®), is more effective than another approved drug, letrozole (Femara®), in delaying the growth of breast cancer in postmenopausal patients with locally advanced or metastatic breast cancer, and whether the side effects of the combination are different from the side effects of letrozole.

NCT ID: NCT00043927 Completed - Clinical trials for Small Cell Lung Cancer

Extensive Small Cell Lung Cancer Treatment Using An Investigational Drug Plus Chemotherapy In Chemotherapy-Naive Adults

Start date: April 2001
Phase: Phase 3
Study type: Interventional

This study will gather and compare data about the effectiveness and safety of two different treatments for extensive Small Cell Lung Cancer (SCLC) in patients who have not received previous chemotherapy. One treatment will use an investigational drug in combination with an FDA approved chemotherapy. The other treatment will use a combination of two FDA approved chemotherapy drugs.

NCT ID: NCT00042068 Completed - Clinical trials for Arthritis, Rheumatoid

A Multi-Center Trial to Compare Three Doses of Meloxicam and Placebo in Patients With Rheumatoid Arthritis

Start date: June 2002
Phase: Phase 3
Study type: Interventional

A 12-week trial consisting of 5 visits (6 if follow up is needed) to find out how effective and safe three different doses of meloxicam are compared with placebo in Rheumatoid Arthritis. Patient will take one dose of study medication daily.

NCT ID: NCT00039910 Completed - Clinical trials for Non-Hodgkin Lymphoma

Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia

Start date: July 2000
Phase: Phase 3
Study type: Interventional

Intensive chemotherapy is associated with significant thrombocytopenia, often requiring platelet transfusion to maintain platelet counts. This investigational drug has been demonstrated to increase platelet counts. This study will test the safety and efficacy of the investigational drug in the prevention of thrombocytopenia in patients with recurrent or refractory intermediate-grade or high-grade non-Burkitt's, non-Hodgkin's lymphoma (NHL), or Hodgkin's disease receiving DHAP (Dexamethasone, high-dose Cytarabine, and Cisplatin) chemotherapy.

NCT ID: NCT00039000 Completed - Malignant Melanoma Clinical Trials

Study of Heat Shock Protein-Peptide Complex (HSPPC-96) Versus IL-2/DTIC for Stage IV Melanoma

Start date: March 2002
Phase: Phase 3
Study type: Interventional

The primary goal of this study is to determine if people with metastatic melanoma who receive Heat Shock Protein-Peptide Complex - 96 (HSPPC-96 or Oncophage) after surgery live longer than people who may or may not have surgery but who receive conventional chemotherapy including IL-2/DTIC. A second goal is to determine the safety and frequency of side effects in subjects who receive therapy with HSPPC-96.

NCT ID: NCT00038467 Completed - Breast Neoplasms Clinical Trials

Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer

IES
Start date: February 1998
Phase: Phase 3
Study type: Interventional

To compare the sequential administration of exemestane with administration of further tamoxifen until 5 years in postmenopausal women with operable breast cancer who have already received 2-3 years of adjuvant tamoxifen, in terms of disease-free survival (DFS), overall survival (OS), incidence of contralateral breast cancer and long-term tolerability.